Skip to main content

Table 1 Prognostic survival analysis results

From: Clinical significance and biological mechanisms of glutathione S-transferase mu gene family in colon adenocarcinoma

Gene

Patients

(n = 438)

No. of events (%)

MST

(days)

Crude HR

(95% CI)

Crude P

Adjusted HR*

(95% CI)

Adjusted P*

GSTM1

 High

219

57 (26.0%)

1849

Ref.

0.018

Ref.

0.006

 Low

219

41 (18.7%)

3042

0.614 (0.410–0.919)

 

0.559 (0.367–0.849)

 

GSTM2

 High

219

59 (26.9%)

2047

Ref.

0.003

Ref.

0.002

 Low

219

39 (17.8%)

2821

0.545 (0.364–0.818)

 

0.519 (0.342–0.790)

 

GSTM3

 High

219

45 (20.5%)

3042

Ref.

0.804

Ref.

0.469

 Low

219

53 (24.3%)

2134

0.804 (0.540–1.197)

 

0.860 (0.571–1.295)

 

GSTM4

 High

219

46 (21.0%)

3042

Ref.

0.387

Ref.

0.729

 Low

219

52 (23.7%)

2134

0.839 (0.563–1.249)

 

0.930 (0.618–1.400)

 

GSTM5

 High

219

53 (24.2%)

2134

Ref.

0.495

Ref.

0.903

 Low

219

45 (20.5%)

2821

1.148 (0.772–1.709)

 

0.975 (0.647–1.468)

 
  1. Notes: *, adjustment for tumor stage
  2. Abbreviations: GSTM, Glutathione S-transferase Mu; MST, median survival time; HR, hazard ratio; CI, confidence interval